Research programme: ROR gamma modulators - Amgen/Teijin PharmaAlternative Names: ROR-gamma modulators - Amgen/Teijin Pharma
Latest Information Update: 12 Aug 2013
At a glance
- Originator Amgen; Teijin Pharma
- Class Small molecules
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders
Most Recent Events
- 31 Jul 2013 Early research in Autoimmune disorders in USA and Japan (unspecified route)